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ABSTRACT
Objectives: An unlinked anonymous seroprevalence
study was conducted to estimate the prevalence of
hepatitis C virus (HCV) infection in samples derived
from antenatal clinic attendees at 2 East London
Hospitals. An unexpectedly high HCV seroprevalence of
2.6% (1.2% viraemic) had been revealed during an
unlinked study of the emergency department at 1 of
these hospitals.
Design: 1000 stored residual samples were tested for
HCV antibody (anti-HCV) and reactive samples were
further tested for HCV RNA. The study was reviewed by
the East Midland NRES ethics committee project ID
181154, approval number 15/WS/0125.
Results: The anti-HCV reactivity rate was 0.5%
(5/1000) with 0.1% (1/1000) confirmed viraemic.
Prevalence for the other blood-borne viruses was
higher: 1% (10/1000) were hepatitis B surface antigen
positive and 0.3% were HIV antigen/antibody positive
(3/1000). There were no co-infections.
Conclusions: More data to establish the prevalence of
HCV in the antenatal population is needed. The
addition of anti-HCV testing to the well-established
antenatal screening programme provides a unique
opportunity to impact on the health of pregnant
women, their children, partners and future pregnancies
in this new era of treatment for hepatitis C.
BACKGROUND
With around 130–170 million people living
with hepatitis C virus (HCV) worldwide,
HCV is clearly a signiﬁcant global public
health concern.1 In the UK, about 160 000
people are chronically infected with HCV
and the prevalence is estimated to be 0.4%.2
One-quarter of those infected in the UK live
in London.3 Hospitalisations associated with
HCV-related end-stage liver disease, hepato-
cellular carcinoma, liver transplant and
death are rising year on year.2 Directly acting
antiviral (DAA) therapies for HCV now offer
close to 100% cure rates, are tolerable, of
short duration and currently accessible on
the British National Health Service (NHS)
for those with HCV and cirrhosis.4 5
In the UK, half of those infected with HCV
are undiagnosed.3 While universal screening
for other blood-borne viruses (BBVs) such as
HIV is recommended in the UK and the
USA, no such universal recommendations
exist for HCV.6 7 In the USA, the Centre for
Disease Control and Prevention (CDC)
recommends one-time HCV ‘birth cohort’
screening for those born between 1945 and
1965.8 In the UK, risk-based HCV testing is
recommended by the National Institute for
Health and Care Excellence (NICE), a strat-
egy acknowledged to underestimate the size
of the problem due to varying interpretation
by clinicians and patients as to what constitu-
tes risk.9 Accurate data are important in
shaping appropriate screening strategies;
however, in England, the estimation of HCV
prevalence varies widely and is informed by
relatively few representative population-based
serosurveys.10
In 2013, there were over 700 000 atten-
dances to antenatal clinics in England with
97.54% having bloods taken for HIV and
97.68% for hepatitis B virus (HBV).11 In the
antenatal setting, HIV and HBV opt-out
screening is recommended and has been
instituted since 1999 to reduce HIV and HBV
transmissions through intervention.12 13
Vertical transmission occurs in 4–8% of HCV
viraemic patients. Studies to determine
Strengths and limitations of this study
▪ The retrospective unlinked design does not allow
clinical correlations to be made.
▪ The study is not powered for comparisons
between age and ethnic groups.
▪ The inclusion criteria may have resulted in the
introduction of bias as patients from ethnic
minorities may be less likely to have accurate
ethnicity data completed.
▪ The findings in our population may not be applic-
able to antenatal clinics in other geographical loca-
tions; local data need to be established for local
hepatitis C virus screening recommendations.
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whether antenatal HCV screening is justiﬁed were last
conducted in the late 1990s, at a time when there was
no possibility of intervention for mother or child and
limited options following delivery.
Following recent advances in hepatitis C treatment,
antenatal clinic screening for HCV needs to be
re-evaluated as it provides a unique opportunity to iden-
tify asymptomatic women of child bearing age with hepa-
titis C.
Antenatal derived data from across the UK have
revealed a seroprevalence ranging from 0.21% to 0.8%
in different regions.14 15 More recent London data have
suggested a prevalence of 0.3–0.4%, with the latter
ﬁgure from another area in East London.16 17 In a retro-
spective review of HCV screening in pregnancies
between 2003 and 2013 at St Mary’s Hospital London,
there were three vertical transmissions.16 In the era of
directly acting agents against hepatitis C, at least some of
these transmissions could be preventable.
We sought to determine the retrospective prevalence
of active HCV infection in samples derived from ante-
natal attendees in two of the hospitals within our NHS
Trust to inform us on the potential beneﬁts of screening
in this population. Both are busy ethnically diverse East
London hospitals. In 2014, an unlinked seroprevalence
survey of the emergency department (ED) at one of
these hospitals revealed a high HCV antibody
(anti-HCV) prevalence of 2.6% (1.2% viraemic).18
METHODS
One thousand residual virology samples derived from
women over the age of 18 years who had attended ante-
natal clinics during 2013 at two London hospitals were
retrospectively tested for anti-HCV in June 2015.
Samples required data regarding age, ethnicity and post
code to be present for inclusion. HIV antibody/antigen
(HIV Ag/Ab) and hepatitis B surface antigen (HBsAg)
results from the original antenatal screen were also col-
lected to allow comparison with the prevalence of these
other BBVs. Sequential samples with these data present
from January 2013 were selected for testing. Previous
anti-HCV results for these patients were available. Five
hundred samples were from the Royal London Hospital
(the same hospital as the ED survey showing a high
HCV prevalence) and 500 were from Newham General
Hospital. Both hospitals serve boroughs falling within
the highest deprivation index quintiles in the country.
Following the acquisition of the list of patient samples
fulﬁlling these criteria, samples were anonymised and
given a unique study number. Those performing the
tests and analysing the data were blinded to any patient
details.
Samples were tested for anti-HCV using an automated
EIA (Architect, Abbott) assay. The previous testing of
HIV Ag/Ab and HBsAg was also performed on this plat-
form. Reactive samples were further tested for HCV
RNA (COBAS Amplicor V.2). Data were statistically
analysed using the SPSS Statistics V.20 software (IBM).
The study was reviewed by the East Midland NRES ethics
committee and approved.
RESULTS
One thousand samples were tested during the study
period. Age range was 15–49 years (median 29; table 1).
The main ethnicity groups were Asian (478/1000),
white European (148/1000), white British and Irish
(121/1000) and African 110/1000). Overall, 5/1000
(0.5%; 95% CI 0.06% to 0.94%) samples were reactive
for anti-HCV and 1/1000 (0.1%; 95% CI 0% to 0.3%)
was HCV RNA positive. Two of the ﬁve anti-HCV positive
samples had previous positive tests on our system, includ-
ing the HCV RNA-positive individual. Four of the ﬁve
reactive samples were in the 25–34-year age group.
The prevalence of HBV and HIV was higher: 1% (10/
1000; 95% CI 0.38% to 1.62%) were HBsAg positive;
0.3% were HIV Ag/Ab positive (3/1000; 95% CI 0% to
0.64%). The HBV cases were aged 25–43 years and
mainly of African (40%), Asian (30%) and Chinese
(20%) ethnicities. The HIV cases were aged 33–39 years
and of African ethnicity. There were no co-infections
(tables 1 and 2). It is not possible to establish from these
data if any of these infections were newly identiﬁed.
Data from the seroprevalence survey in the ED
showed an age-speciﬁc and gender-speciﬁc prevalence
for HCV and a predominant white British ethnicity.
This antenatal cohort was signiﬁcantly younger than
the ED cohort (median of 29 vs 48 years, p<0.001,
Mann-Whitney U test). However, owing to the very small
numbers, it is difﬁcult to comment meaningfully on
ethnicity.
CONCLUSIONS
The prevalence of HCV varies greatly by country world-
wide. The lowest rates are observed in northern
European countries, with progressively higher rates of
infection noted in southern Europe, Asia and
Africa.19 20 Particularly high rates of infection are seen
in Egypt, Pakistan and China.21 Seroprevalence studies
examining vertical transmission of hepatitis C in the UK
Table 1 Prevalence of hepatitis C, hepatitis B and HIV by
age group
Age
group
Total
cohort
Reactive
anti-HCV
HCV
RNA
positive
HBsAg
detected
HIV
Ag/Ab
positive
15–24 184 0 0 0 0
25–34 642 4 1 7 1
35–44 170 1 0 3 2
45–54 4 0 0 0 0
Total 1000 5 1 10 3
HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; HIV Ag/
Ab, HIV antibody/antigen.
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have reﬂected this variation, with subgroup analysis dem-
onstrating a higher prevalence of HCV in mothers born
outside of the UK.22
We found the seroprevalence for anti-HCV to be 0.5%
(0.1% viraemic) in our antenatal population, similar to
the stated national prevalence of 0.4%2 and to the preva-
lence observed in previous antenatal studies performed
in other areas of the UK.14 16 17 The prevalence is 2.1%
lower than in the ED of the same hospital.18 It is pos-
sible that the inclusion criteria for the current study
introduced bias due to the requirement for speciﬁc
sample information to be present—this information is
less likely to be complete for ethnic minority popula-
tions most likely to be at risk of HCV. The HCV RNA
prevalence in this group was lower than that for HIV
Ag/Ab and HBsAg, both of which are currently
screened for antenatally.
The small number of positive samples in this study
does not allow for comparison between age and ethnic
groups. Any comparisons between the ED and the ante-
natal cohorts are biased because of the differences in
sample acquisition and because they reﬂect very differ-
ent opportunities for identifying infection. The ED
population represents a diverse population unwell and
in need of emergency care prospectively sampled,
whereas the antenatal cohort represents a population
which is in general asymptomatic.
The US CDC currently only recommends screening
for hepatitis C in persons considered to be at high risk
of infection. It applies these guidelines to the antenatal
population and does not recommend routine screening
for hepatitis C in pregnant women. The European
Centre for Disease Prevention and Control technical
report on surveillance in 2010 demonstrates that ante-
natal HBsAg screening is widespread, but antenatal
screening for hepatitis C is currently only undertaken in
Spain and Norway.23 A 2005 economic analysis based on
the US setting concluded that screening of asymptom-
atic pregnant woman for HCV was not cost-effective for
the US model at that time. The modelling used is not
applicable to the UK system of healthcare, or to the
current recommendations for management of pregnant
women with HCV. In addition, it could not consider the
new DAA treatments.24
Recent modelling has been performed on antenatal
populations in the UK and the Netherlands with superﬁ-
cially contrasting results. Selvapatt and colleagues mod-
elled the cost-effectiveness of antenatal hepatitis C
screening using their data from St Mary’s Hospital,
London.16 Utilising the MONARCH (Modelling the
Natural History and Cost-effectiveness of Hepatitis C)
model, which has previously been published and vali-
dated, they demonstrated cost-effectiveness in a variety
of scenarios, including the use of newer DAAs.25 After
discussing possible underestimations, they found that
the quality-adjusted life years (QALYs) associated with
effective treatment far outstripped the costs of imple-
menting screening and providing treatment. In contrast,
a study of anti-HCV antenatal screening in the Dutch
health system found that implementation was not cost-
effective, though Selvapatt indicated that this was due to
high costs of screening and treatment, and the use of
outcome measures which underestimates beneﬁts of
treatment in relation to quality of life. The St Mary’s
group took the Dutch ﬁgures and adapted them with
lower treatment costs and found the screening pro-
gramme to be cost-effective for the previously applied
threshold of €20 000 per QALYs. The St Mary’s study
and the adaptations that its authors made to the Dutch
study data appear to indicate that even with the current
high costs of DAAs, their high cure rate indicates prob-
able cost-effectiveness even with active case ﬁnding.
Our study provides a snapshot of seroprevalence of
anti-HCV in the antenatal population at two busy East
London Hospitals. Owing to the methodology employed
in sample acquisition, it is most likely that the results are
an underestimation of the true size of the problem and
this warrants further investigation with prospective anon-
ymised sampling of the antenatal cohort.
Extrapolating the prevalence of our study, with over
700 000 antenatal clinic attendances nationally, 700 vir-
aemic women could be identiﬁed annually, with potential
for further viraemic individuals to be identiﬁed through
contact screening. With current high throughput multiple
Table 2 Prevalence of hepatitis C, hepatitis B and HIV by ethnicity
Ethnicity
Total
cohort
Reactive
anti-HCV
HCV RNA
positive
HBsAg
detected
HBsAg
prevalence
HIV Ag/Ab
positive
HIV
prevalence
White (British and Irish) 121 0 0 0 0.00 0 0.00
Black (British and other) 29 0 0 1 3.45 0 0.00
White (European and other) 148 2 0 0 0.00 0 0.00
Caribbean (white and black) 30 0 0 0 0.00 0 0.00
African 110 1 1 4 3.64 3 2.73
Asian 478 2 0 3 0.63 0 0.00
Chinese 23 0 0 2 8.70 0 0.00
Middle Eastern 2 0 0 0 0.00 0 0.00
Other 59 0 0 0 0.00 0 0.00
HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; HIV Ag/Ab, HIV antibody/antigen.
Orkin C, et al. BMJ Open 2016;6:e010661. doi:10.1136/bmjopen-2015-010661 3
Open Access
testing platforms, the costs of adding anti-HCV to samples
that have already been acquired as part of routine ante-
natal screening are minimal, negating further phlebotomy
equipment or services costs. From a laboratory perspective,
the addition of a test to an existing sample would minim-
ally impact on laboratory staff. With the number of positive
results demonstrated in our and other seroprevalence
studies, the impact on workload for those analysing results
should be easily accommodated.
The face of hepatitis C treatment has completely
changed in recent years and antenatal screening provides
us with a unique opportunity to intervene in a population
for which it has previously been deemed unproductive.
Screening of pregnant women can impact multiple people
at multiple points: it allows for appropriate management
of the current pregnancy, reducing vertical transmission
by informing the obstetric team to avoid use of obstetric
interventions; babies born to mothers with HCV can be
monitored and provided with treatment as necessary post-
delivery; the mother herself can be provided with treat-
ment, impacting not just her own health, but the health of
future pregnancies; contact screening of partners and pre-
vious children might identify other asymptomatic carriers,
allowing them to access treatment. Clinical trials using
DAAs for children with hepatitis C are currently under-
way.26 Identifying a hepatitis C viraemic mother at ante-
natal screening has the potential to impact on many more
lives. The longer term advantages of reducing the hepatitis
C burden as well as the personal implications for women
and their families cannot be underestimated.
Prior to the advent of DAAs, HCV was not considered
worthy of antenatal screening because of a lack of
options for intervention. The landscape has dramatically
changed and it is time that we adapt to reﬂect this with
our screening strategies.
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